Antibodies to citrullinated protein antigens (ACPAs): Clinical and pathophysiologic significance

Current Rheumatology Reports

Volumn 13, Issue 5, 2011, Pages 421-430

  Demoruelle, M Kristen ^a   Deane, Kevin ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

ACPAs; Anti CCP antibody; Antibodies to citrullinated peptide antigens; Anticyclic citrullinated peptide antibody; Autoimmunity; Diagnosis; Pathogenesis; Rheumatoid arthritis

Indexed keywords

AUTOANTIBODY; CITRULLINATED PROTEIN ANTIGEN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; UNCLASSIFIED DRUG; VIMENTIN ANTIBODY;

ARTICLE; AUTOIMMUNITY; CHEMICAL MODIFICATION; CITRULLINATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG RESPONSE; ENVIRONMENTAL FACTOR; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; RHEUMATOID ARTHRITIS; RISK FACTOR;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNITY; HUMANS; PEPTIDES, CYCLIC;

EID: 80755128527     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0193-7     Document Type: Article

References (74)

1. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5 SUPPL. 5):S35-61.
2. Allaart CF, Breedveld FC, Dijkmans BA. Treatment of recentonset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol SUPPL. 2007;80:25-33. (Pubitemid 350076865)
3. • Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A, Burke M, et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010, 152(7):456-64; W155-66. This study provides a comprehensive review of the diagnostic accuracy of anti-CCP testing in RA.
4. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651-75. (Pubitemid 351600388)
5. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis. 1964;23:302-5.
6. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995, 95(6):2672-9.
7. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Antikeratin antibodies in rheumatoid arthritis. Br Med J. 1979, 2(6182):97-9.
8. Simon M, Girbal E, Sebbag M, Gomes-Daudrix V Vincent C, Salama G, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies', autoantibodies specific for rheumatoid arthritis. J Clin Invest. 1993, 92(3):1387-93. (Pubitemid 23273915)
9. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998, 101(1):273-81. (Pubitemid 28058927)
10. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000, 43(1):155-63. (Pubitemid 30368225)
11. van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anticyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis. 2005, 64(10):1510-2. (Pubitemid 41623868)
12. Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EK, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008, 58(6):1576-81. (Pubitemid 351847510)
13. INOVA Diagnostics SD, California, U. S. A. QUANTA Lite CCP IgG ELISA [package insert, revision 9]. 2005.
14. Axis-Shield LD. Scotland, U. K. Axis Shield anti-CCP2 [package insert]. 2008; Available at http://wwwaxis-shield.com/sites/axisshield/files/documents/ ASD%20Anti-CCP400% 20PI-R1-EN.pdf
15. van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig-Meyling FH, van Booma-Frankfort C, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol. 1999, 17(6):689-97.
16. Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol. 2004, 135(1):173-80. (Pubitemid 38067943)
17. INOVA Diagnostics SD, California, U. S. A. QUANTA Lite CCP3 IgG ELISA [package insert, revision 6]. 2010; Available at www.inovadx.com/pdfdi/704535- en.pdf
18. INOVA Diagnostics SD, California, U. S. A. QUANTA Lite CCP3.1 IgG/IgA ELISA [package insert, revision 2]. 2009; Available at www.inovadx.com/pdf/di/ 704550-en.pdf
19. Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol. 1994, 21(6):1027-33. (Pubitemid 24182272)
20. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6(2):R142-50.
21. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther. 2006;8(4):R119.
22. Luime JJ, Colin EM, Hazes JM, Lubberts E. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis. 2010, 69(2):337-44.
23. El-Gabalawy HS, Robinson DB, Hart D, Elias B, Markland J, Peschken CA, et al. Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol. 2009, 36(6):1130-5.
24. Lee DM, Phillips R, Hagan EM, Chibnik LB, Costenbader KH, Schur PH. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis. 2009, 68(2):201-8.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31(3):315-24. (Pubitemid 18091653)
26. • Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62(9):2569-81. This paper proposes the new ACR/EULAR classification criteria for RA.
27. Liao KP, Batra KL, Chibnik L, Schur PH, Costenbader KH. Anticyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis. 2008, 67(11):1557-61.
28. van Der Linden MP, Knevel R, Huizinga TW van der Helm-van Mil AH. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum. 2011, 63(1):37-42.
29. van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 2008, 58(8):2241-7.
30. de Rooy DP, van Der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011, 50(1):93-100.
31. Pinheiro GC, Scheinberg MA, Aparecida da Silva M, Maciel S. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med. 2003, 139(3):234-5. (Pubitemid 38124610)
32. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004, 63(9):1085-9. (Pubitemid 39120359)
33. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004, 63(9):1090-5. (Pubitemid 39120360)
34. Sihvonen S, Korpela M, Mustila A, Mustonen J. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005, 32(11):2089-94. (Pubitemid 41587850)
35. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007, 56(5):1424-32. (Pubitemid 46764069)
36. Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R76.
37. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009, 68(1):69-74.
38. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Loet XL, et al. B-cell activation biomarkers as predictive factors of the response to rituximab in rheumatoid arthritis. Arthritis Rheum. 2011 Jan 10.
39. Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009, 48(12):1557-9.
40. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2006, 65(1):35-9. (Pubitemid 41815636)
41. Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004, 50(12):3776-82. (Pubitemid 39643924)
42. Miriovsky BJ, Michaud K, Thiele GM, O'Dell JR, Cannon GW, Kerr G, et al. Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis. 2010, 69(7):1292-7.
43. Nicaise Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G, et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther. 2008;10(6):R142.
44. Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011, 63(1):26-36.
45. Brunner JK, Sitzmann FC. Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Mod Rheumatol. 2006, 16(6):372-5. (Pubitemid 44921585)
46. Kakumanu P, Sobel ES, Narain S, Li Y, Akaogi J, Yamasaki Y, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol. 2009, 36(12):2682-90.
47. Qing YF, Zhang QB, Zhou JG, Yuan GH, Wei J, Xing Y, et al. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus. 2009, 18(8):713-7.
48. Generini S, Steiner G, Miniati I, Conforti ML, Guiducci S, Skriner K, et al. Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. Rheumatology (Oxford). 2009, 48(8):920-5.
49. Morita Y, Muro Y, Sugiura K, Tomita Y. Anti-cyclic citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol. 2008, 26(4):542-7.
50. Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol. 2008, 27(1):77-83. (Pubitemid 350182681)
51. Alenius GM, Berglin E, Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis. 2006, 65(3):398-400. (Pubitemid 43268233)
52. Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis. 2005, 64(8):1145-9. (Pubitemid 41113348)
53. Ceri M, Unverdi S, Altay M, Ureten K, Ozturk MA, Gonen N, et al. Anti-cyclic citrullinated peptides positivity rate in patients with familial Mediterranean fever. Clin Exp Rheumatol. 2010;28(4 SUPPL. 60):S58-61.
54. Karatay S, Yildirim K, Erdal A, Uzkeser H, Erdem FH, Yanmaz V. Anti-cyclic citrullinated peptide antibodies are not associated with familial Mediterranean fever. J Back Musculoskelet Rehabil. 2010, 23(1):21-3.
55. Wu R, Shovman O, Zhang Y, Gilburd B, Zandman-Goddard G, Shoenfeld Y. Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. Clin Rev Allergy Immunol. 2007, 32(1):47-56.
56. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem. 2007, 53(3):498-504. (Pubitemid 46447947)
57. Ingegnoli F, Galbiati V, Zeni S, Meani L, Zahalkova L, Lubatti C, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol. 2007, 26(4):510-4. (Pubitemid 46359289)
58. Elkayam O, Segal R, Lidgi M, Caspi D. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006, 65(8):1110-2. (Pubitemid 44133278)
59. Elkayam O, Segal R, Bendayan D, van Uitert R, Onnekink C, Pruijn GJ. The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment. Arthritis Res Ther. 2010;12(1):R12.
60. Gyorgy B, Toth E, Tarcsa E, Falus A, Buzas EI. Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol. 2006, 38(10):1662-77. (Pubitemid 43947646)
61. *0401 MHC class II molecule. J Immunol. 2003, 171(2):538-41. (Pubitemid 36871358)
62. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006, 54(1):38-46. (Pubitemid 43122184)
63. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med. 2008, 205(4):967-79. (Pubitemid 351549891)
64. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006, 116(4):961-73.
65. Feitsma AL, van der Voort EI, Franken KL, el Bannoudi H, Elferink BG, Drijfhout JW, et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum. 2010, 62(1):117-25.
66. Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum. 2011, 63(1):53-62.
67. Kochi Y Suzuki A, Yamada R, Yamamoto K. Genetics of rheumatoid arthritis: underlying evidence of ethnic differences. J Autoimmun. 2009;32(3-4):158-62.
68. Aho K, Palosuo T, Heliovaara M, Knekt P, Alha P, von Essen R. Antifilaggrin antibodies within "normal' range predict rheumatoid arthritis in a linear fashion. J Rheumatol. 2000, 27(12):2743-6.
69. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004, 50(2):380-6. (Pubitemid 38198821)
70. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48(10):2741-9. (Pubitemid 37280601)
71. Majka DS, Deane KD, Parrish LA, Lazar AA, Baron AE, Walker CW, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis. 2008, 67(6):801-7. (Pubitemid 351829380)
72. • Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ. Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol. 2010, 6(12):727-30. This paper provides an overview of how peridontal infection may lead to initial RA-related autoimmunity.
73. Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010, 36(2):213-41.
74. Barra L, Pope J, Bessette L, Haraoui B, Bykerk V Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology (Oxford). 2010 Jul. 9.